Sysmex (OTCMKTS:SSMXY) Sees Unusually-High Trading Volume – Still a Buy?

Sysmex Corporation ADR (OTCMKTS:SSMXY) shares saw strong trading volume on Monday . 917,331 shares changed hands during mid-day trading, an increase of 244% from the previous session’s volume of 266,905 shares.The stock last traded at $8.69 and had previously closed at $8.69.

Analyst Upgrades and Downgrades

Separately, Citigroup cut shares of Sysmex from a “strong-buy” rating to a “hold” rating in a report on Monday, March 16th. One analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold”.

Sysmex Stock Up 0.7%

The company has a quick ratio of 2.44, a current ratio of 3.33 and a debt-to-equity ratio of 0.12. The stock has a market cap of $5.51 billion, a price-to-earnings ratio of 18.24 and a beta of 1.13. The business’s fifty day moving average is $8.94 and its two-hundred day moving average is $9.94.

Sysmex (OTCMKTS:SSMXY) last announced its quarterly earnings data on Thursday, February 12th. The company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.01. The firm had revenue of $837.32 million during the quarter, compared to analysts’ expectations of $819.99 million. Sysmex had a net margin of 8.86% and a return on equity of 9.27%. Equities analysts forecast that Sysmex Corporation ADR will post 0.57 earnings per share for the current fiscal year.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.